Quanterix
QTRX
Market cap $229M

5.89 USD

+0.03

0.51%

At close Jul 11, 4:00 PM EDT

After hours

6.00

+0.11

1.87%

1 day

0.51%

5 days

-15.01%

1 month

-11.56%

3 months

13.27%

6 months

-35.35%

Year to date

-45.26%

1 year

-58.17%

5 years

-78.12%

10 years

-66.29%

About: Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.

Employees: 136

Healthcare Medical Devices

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

60% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 35

46% more call options, than puts

Call options by funds: $168K | Put options by funds: $115K

0% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 37

0.48% less ownership

Funds ownership: 90.88% [Q4 2024] → 90.4% (-0.48%) [Q1 2025]

2% less funds holding

Funds holding: 152 [Q4 2024] → 149 (-3) [Q1 2025]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]

39% less capital invested

Capital invested by funds: $372M [Q4 2024] → $228M (-$144M) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

36%

upside

Avg. target

$10

70%

upside

High target

$12

104%

upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Canaccord Genuity Kyle Mikson	104%upside $12	Buy Maintained	13 May 2025
Leerink Partners Puneet Souda	36%upside $8	Market Perform Downgraded	30 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about QTRX published over the past 30 days

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units (“RSUs”) representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasd.

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets. Under the terms of the amended merger agreement announced on April 29th, Quanterix issued app.

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum

Quanterix Expands Reach with IVD and Large Reference Labs

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems. The continued expansion of the industry-leading Simoa® technology platform into global markets demonstrates a key mil.

Quanterix Expands Reach with IVD and Large Reference Labs

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

RINCON, Puerto Rico , June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time. "Quanterix's ongoing failure to schedule its 2025 Annual Meeting until the approaching legal deadline is consistent with the Board's pattern of limiting and disregarding shareholder input.

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

Quanterix to Present at Goldman Sachs Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast prese.

Quanterix to Present at Goldman Sachs Global Healthcare Conference

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ: AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya.

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

Quanterix Corporation (NASDAQ:QTRX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Joshua Young - Head, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Kyle Mikson - Canaccord Sung Ji Nam - Scotiabank Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today.

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.26 per share a year ago.

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

Quanterix Releases Financial Results for the First Quarter of 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward,” said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new earl.

Quanterix Releases Financial Results for the First Quarter of 2025

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to.

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

See News Rankings

Charts implemented using Lightweight Charts™